GANITE
LOE Approachinggallium nitrate
NDAINJECTIONINJECTABLEPriority Review
Approved
Jan 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 18h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GANITE (gallium nitrate) is an intravenous injectable agent approved in 1991 for treating hypercalcemia of malignancy. The mechanism of action and specific indications are not detailed in available data, but gallium nitrate functions as a calcium-regulating agent used in oncology settings.
LOE Approaching
This product is in late-stage decline with competitive pressure rated at 30%, indicating a contracting commercial opportunity and likely reduced team investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
GANITE offers minimal career opportunity; the product has zero linked job openings and is approaching loss of exclusivity with declining market relevance. Professionals considering this role should expect portfolio contraction and potential reassignment rather than growth trajectories.
Brand ManagerField Sales Representative
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.